According to BeiGene
's latest financial reports the company has $3.17 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $3.17 B | -30% |
2022-12-31 | $4.53 B | -31.47% |
2021-12-31 | $6.61 B | 42.29% |
2020-12-31 | $4.65 B | 373.24% |
2019-12-31 | $0.98 B | -44.83% |
2018-12-31 | $1.78 B | 112.71% |
2017-12-31 | $0.83 B | 127.48% |
2016-12-31 | $0.36 B | 266.39% |
2015-12-31 | $0.10 B | 126.35% |
2014-12-31 | $44.39 M | 1030.79% |
2013-12-31 | $3.92 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | $95.88 M | -96.98% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | $25.24 M | -99.20% | ๐บ๐ธ USA |